Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623879 | 1.00 | BCL2 (0.57) | BCL2MGLLHSD17B1TDP2MAPT | |
| SCHEMBL17568796 | 0.86 | TAAR1 (0.52) | MGLLTDP2MAPTSMN1; SMN2PGR | |
| SCHEMBL13756311 | 0.86 | BCL2 (0.71) | BCL2PTGS2DHFR | |
| SCHEMBL10243325 | 0.86 | BCL2 (0.71) | BCL2PTGS2DHFR | |
| SCHEMBL2586835 | 0.85 | KMO (0.59) | TDP2MAPTSMN1; SMN2PGRDHFR | |
| SCHEMBL10243641 | 0.85 | BCL2 (0.55) | BCL2MGLLTDP2 | |
| SCHEMBL28116916 | 0.85 | MAPT (0.56) | BCL2MAPTSMN1; SMN2PTGS2DHFR | |
| SCHEMBL10243328 | 0.85 | BCL2 (0.55) | BCL2MGLLTDP2 | |
| SCHEMBL31195750 | 0.84 | RARB (0.58) | MGLLMAPT | |
| SCHEMBL10389377 | 0.83 | MAPT (0.69) | HSD17B1TDP2MAPTSMN1; SMN2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130225621-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | UNIVERSITY OF TORONTO MISSISSAUGA (CA) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | BCL2 101/4885MGLL 4686/4885HSD17B1 3017/4885 |
| US-20130225621-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | BCL2 101/4885MGLL 4686/4885HSD17B1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.